ReviewCEN case reports2026
Durvalumab-associated membranous nephropathy: a case report and brief literature review.
Review in CEN case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Durvalumab-associated nephrotic syndrome and organizing pneumonia: a case report.CEN case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors can trigger renal immune-related adverse events, including glomerular disease. We report an 84-year-old man with non-small cell lung cancer who developed nephrotic syndrome after starting durvalumab. Proteinuria rose to 4+ four weeks into durvalumab therapy, and by week 6 serum albumin had fallen to 2.7 g/dL, prompting discontinuation. He was referred in January 2024 with serum albumin 2.0 g/dL and a urine protein-creatinine ratio of 13.57 g/gCr. Kidney biopsy demonstrated membranous nephropathy: capillary-wall thickening with spike formation on PAM, granular capillary-wall IgG on immunofluorescence, and scattered subepithelial deposits with widespread foot-process effacement on electron microscopy. IgG subclass staining showed a non-IgG4-dominant pattern (IgG1 > IgG4 > IgG2 > IgG3), supporting secondary MN in the setting of ICI exposure. Prednisolone 0.7 mg/kg/day (50 mg/day) was initiated, inducing complete remission by day 13, with sustained remission during taper to 5 mg/day. To our knowledge, this is the first report of de novo MN temporally associated with durvalumab; together with the available literature on ICI-associated MN, these findings support prednisolone (glucocorticoids) as a reasonable first-line therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.